<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872636</url>
  </required_header>
  <id_info>
    <org_study_id>DK-0000-001-306</org_study_id>
    <nct_id>NCT02872636</nct_id>
  </id_info>
  <brief_title>Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter</brief_title>
  <acronym>PILLAR</acronym>
  <official_title>Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minnetronix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minnetronix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this feasibility study is to demonstrate the safety and feasibility of using&#xD;
      an investigational extracorporeal system and catheter to filter hemorrhagic cerebrospinal&#xD;
      fluid (CSF) post subarachnoid hemorrhage (SAH) treatment, and reintroduce the CSF via the&#xD;
      same catheter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2017</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">April 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device/System Safety - Adverse events related to the filtration procedure</measure>
    <time_frame>30 days</time_frame>
    <description>Adverse events related to the filtration procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events related to the system catheter insertion</measure>
    <time_frame>30 days</time_frame>
    <description>Nerve or tissue damage related to catheter insertion</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spinal catheter insertion with extracorporeal filtration of CSF</intervention_name>
    <description>Extracorporeal filtration of CSF</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 years or older&#xD;
&#xD;
          -  Informed consent by the patient or his/her legally authorized representative&#xD;
&#xD;
          -  Modified Fisher Grade 2, 3, or 4&#xD;
&#xD;
          -  Hunt &amp; Hess I-III&#xD;
&#xD;
          -  First aneurysmal SAH that has been confirmed by Angio, CTA or MRA&#xD;
&#xD;
          -  Patient is â‰¤ 48 hours post bleeding event&#xD;
&#xD;
          -  World Federation of Neurosurgeons (WFNS) Grades I-IV and those Grade V patients who&#xD;
             improve to Grade IV or less after ventriculostomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a SAH due to mycotic aneurysm or AV malformation&#xD;
&#xD;
          -  Patients who present with an acute MI or unstable angina&#xD;
&#xD;
          -  Patients with uncontrolled diabetes&#xD;
&#xD;
          -  Patients who present with a creatinine &gt; 2.0mg/dl&#xD;
&#xD;
          -  Imaging demonstrates supratentorial mass lesions greater than 50 cc&#xD;
&#xD;
          -  Imaging demonstrates more than 5 mm of mid-line-shift associated with infarction and&#xD;
             or edema&#xD;
&#xD;
          -  Effacement of the basilar cisterns (suprasellar, ambient, chiasmatic and&#xD;
             quadrageminal)&#xD;
&#xD;
          -  Vasospasm on admission as defined by angiographic evidence&#xD;
&#xD;
          -  Patients with a coagulopathy that cannot be reversed per the professional discretion&#xD;
             of the investigator&#xD;
&#xD;
          -  Thrombocytopenia def. platelet count &lt; 100,000&#xD;
&#xD;
          -  Patients on low molecular weight heparin e.g., Lovenox&#xD;
&#xD;
          -  Patients on Clopidogrel bisulfate (Plavix) or other chronic platelet inhibitors&#xD;
&#xD;
          -  Patients with a documented history of cirrhosis&#xD;
&#xD;
          -  Patients who will be managed with supportive care rather than intervention&#xD;
&#xD;
          -  Obstructive hydrocephalus i.e., non-communicating&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of posterior fusion hardware that would interfere with placement of the&#xD;
             catheter&#xD;
&#xD;
          -  Pre-existing Lumbar Drain&#xD;
&#xD;
          -  Local skin infections or eruptions over the puncture site&#xD;
&#xD;
          -  Signs of systemic infection/sepsis or pneumonia&#xD;
&#xD;
          -  Lumbar puncture within 6 hours&#xD;
&#xD;
          -  Concurrent participation in another study which is not observational or retrospective&#xD;
             in nature without prior approval from the Sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Messer</last_name>
    <role>Study Director</role>
    <affiliation>Minnetronix</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 5, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

